• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avalon GloboCare Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/9/26 5:15:29 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALBT alert in real time by email
    false 0001630212 0001630212 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) June 9, 2026

     

    AVALON GLOBOCARE CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38728   47-1685128
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I. R. S. Employer
    Identification No.)

     

    4400 Route 9 South, Suite 3100, Freehold, NJ 07728

    (Address of principal executive offices, including ZIP code)

     

    (732) 780-4400

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, $0.0001 par value   ALBT   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 9, 2026, Avalon GloboCare Corp. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) for the purpose of holding a stockholder vote on Proposals 1, 2, 3, 4, 5, and 6 set forth below. A total of 4,364,690 shares of the Company’s common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.

     

    At the Annual Meeting, the Company’s stockholders:

     

    1. Elected four (4) members of the Company’s board of directors (the “Board”) to serve for a one-year term to expire at the 2027 annual meeting of stockholders;
       
    2. Ratified the appointment of M&K CPAS, PLLC (“M&K”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;
       
    3. Approved the Avalon GloboCare Corp. 2026 Stock Incentive Plan (the “2026 Plan Proposal”);
       
    4. Approved, on an advisory basis, the 2025 compensation of our named executive officer (the “Say-on-Pay Proposal”);

     

    5. Approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), (i) the issuance of Series A-1 warrants to purchase up to 6,372,550 shares of common stock (the “Series A-1 Warrants”), (ii) the issuance of Series A-2 warrants to purchase up to 6,372,550 shares of common stock (the “Series A-2 Warrants” and together with the Series A-1 Warrants, the “Warrants”), (iii) the issuance of warrants (the “Placement Agent Warrants”) to purchase up to 318,628 shares of common stock issued to H.C. Wainwright & Co., LLC (the “Placement Agent”) and (iv) the shares of common stock issuable upon the exercise of the Warrants and the Placement Agent Warrants all issued in connection with our private placement that closed on February 27, 2026 (the “February 2026 Warrant Issuance Proposal”); and
       
    6. Approved a proposal to give the Board the authority, at its discretion, to file a certificate of amendment to the Company’s amended and restated certificate of incorporation, as amended (“Certificate of Incorporation”), to effect a reverse split of the Company’s issued common stock at a ratio that is not less than 1-for-2 and not greater than 1-for-25, without reducing the authorized number of shares of the Company’s common stock, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following stockholder approval of the amendment to the Company’s Certificate of Incorporation and before June 9, 2027 without further approval or authorization of the stockholders (the “Reverse Stock Split Proposal”).

      

    The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting, as set forth in the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 17, 2026, are as follows:

     

    Proposal 1. At the Annual Meeting, the terms of all current members of the Company’s board of directors expired. All of the four (4) nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four (4) directors were as follows:

     

    Directors  For   Withhold   Broker
    Non-Votes
     
    Wenzhao “Daniel” Lu   1,141,805    359,185    2,863,700 
    Lourdes Felix   1,411,624    89,366    2,863,700 
    Steven A. Sanders   1,435,430    65,560    2,863,700 
    Michael Mathews   1,440,611    60,379    2,863,700 

     

    1

     

     

    Proposal 2. At the Annual Meeting, appointment of M&K as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:

     

    For   Against   Abstain   Broker Non-Votes
    4,250,597   110,736   3,357   0

     

    Proposal 3. At the Annual Meeting, the stockholders approved the 2026 Plan Proposal. The result of the votes to approve the 2026 Plan Proposal was as follows:

     

    For   Against   Abstain   Broker Non-Votes
    880,827   618,585   1,578   2,863,700

     

    Proposal 4. At the Annual Meeting, the stockholders approved the Say-on-Pay Proposal. The result of the votes to approve the Say-on-Pay Proposal was as follows:

     

    For   Against   Abstain   Broker Non-Votes
    1,414,027   32,635   54,328   2,863,700

     

    Proposal 5. At the Annual Meeting, the stockholders approved the February 2026 Warrant Issuance Proposal. The result of the votes to approve the February 2026 Warrant Issuance Proposal was as follows:

     

    For   Against   Abstain   Broker Non-Votes
    925,882   570,691   4,417   2,863,700

     

    Proposal 6. At the Annual Meeting, the stockholders approved the Reverse Stock Split Proposal. The result of the votes to approve the Reverse Stock Split Proposal was as follows:

     

    For   Against   Abstain   Broker Non-Votes
    3,605,584   741,154   17,952   0

      

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 9, 2026 AVALON GLOBOCARE CORP.
       
      /s/ Luisa Ingargiola
      Luisa Ingargiola
      Chief Strategy Officer

     

    3

     

    Get the next $ALBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program

    FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today provided an update on the Nevada POOL/PACT Holistic Health Reset program launched in collaboration with Saga Health and SpecialtyHealth, Inc. The four-month wellness initiative, which began in August 2025, was designed to support 50 first responders through a comprehensive health optimization program focused on improving metabolic, physical, and behavioral wellness outcomes. Participants in the program are util

    6/16/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer

    FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced the appointment of Sam Knipper as Chief Financial Officer, effective June 1, 2026. Mr. Knipper succeeds Luisa Ingargiola, who has served as the Company's Chief Financial Officer since February 2017 and has been appointed as Chief Strategy Officer, where she will continue supporting the Company's long-term strategic initiatives, capital markets activities, and growth opportunities. Mr. Knipper brings

    6/4/26 8:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform Development

    FREEHOLD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced that its subsidiary, Avalon Quantum AI LLC, is collaborating with Amazon Web Services ("AWS") to support Phase 2 development of its Catch-Up agentic AI video platform. Caylent, Inc., an AWS Premier Tier Consulting Partner and a member of the AWS Generative AI Innovation Center's Partner Innovation Alliance, has been appointed to lead the development. Phase 2 of the Catch-Up platform is expected to tr

    4/21/26 8:30:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mathews Michael

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    2/24/26 4:30:28 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Mathews Michael

    3 - Avalon GloboCare Corp. (0001630212) (Issuer)

    2/24/26 4:30:17 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    SEC Filings

    View All

    Avalon GloboCare Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Avalon GloboCare Corp. (0001630212) (Filer)

    6/9/26 5:15:29 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

    8-K - Avalon GloboCare Corp. (0001630212) (Filer)

    6/4/26 4:30:22 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Avalon GloboCare Corp.

    SCHEDULE 13G - Avalon GloboCare Corp. (0001630212) (Subject)

    5/15/26 11:02:42 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Leadership Updates

    Live Leadership Updates

    View All

    Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer

    FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced the appointment of Sam Knipper as Chief Financial Officer, effective June 1, 2026. Mr. Knipper succeeds Luisa Ingargiola, who has served as the Company's Chief Financial Officer since February 2017 and has been appointed as Chief Strategy Officer, where she will continue supporting the Company's long-term strategic initiatives, capital markets activities, and growth opportunities. Mr. Knipper brings

    6/4/26 8:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

    DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ:HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the appointment of Luisa Ingargiola to its Board of Directors, effective February 24, 2025. Ms. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain a member of the Board. She will also serve as a member of the Nominating Committee, Audit Committee, and Compensation Committee. Following Ms. Ingargiola's appointment, the Board will be comprised of six directors, four of whom have been determined by the Board to be "independent directors" under

    2/27/25 8:00:00 AM ET
    $ALBT
    $HTOO
    $VMAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Energy

    Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

    FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epid

    10/31/24 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Financials

    Live finance-specific insights

    View All

    Avalon GloboCare Acquires RPM Interactive, a Generative AI Software Company, in an All-Stock Transaction

    Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders' equity deficiency RPM Interactive has developed a fully automated, generative AI powered SaaS platform for creating short-form video content FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of precision diagnostic consumer products, today announced that it has acquired RPM Interactive, Inc. ("RPM"), a generative artificial intelligence ("AI") publishing and software company, in an all-stock transaction. As a result of the acquisition, the Company believes it

    12/15/25 8:30:00 AM ET
    $ALBT
    $ASPU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Consumer Discretionary

    Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

    FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired Merlin Medical Supply ("MMS"), a profitable, well-established Home Medical Equipment ("HME") and Durable Medical Equipment ("DME") company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontine

    9/13/23 9:15:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

    FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired DE Laboratory LLC ("DE Labs"), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company. Avalon owns a 40% interest in LSM. DE Labs is a CLIA-certified and COLA-accredited laboratory located in Houston, Texas that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing. LSM is no

    7/24/23 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care